NORWELL, Mass.–(BUSINESS WIRE)–For patients and therapists, believing in the benefits
state-of-the-art robotic medical devices bring to the table is one
thing. But having your beliefs incorporated into the official practice
guidelines by associations of experts and authorities in the field is
something entirely different.
Yet this is exactly what is happening. The newest Guidelines for
Adult Stroke Rehabilitation and Recovery from the American Heart
Association/American Stroke Association (AHA/ASA) were recently
published. The following statements can be found in this important
Robot-assisted movement training, to improve motor function and mobility
after stroke in combination with conventional therapy, is beneficial for
Robot-assisted gait training is specifically beneficial for patients who
are non-ambulatory or have low ambulatory ability early after stroke.
Combining robot-assisted gait training with virtual reality can further
be beneficial for the improvement of gait.
Scientific studies back the statements the AHA/ASA are putting forth.
The end goal is to provide a synopsis of best clinical practices in the
rehabilitative care of adults recovering from stroke; and Hocoma fully
agrees with these statements and recommendations.
Hocoma, the world leader in developing advanced medical solutions and
inventor of the most-trusted robotic gait trainer, firmly believes their
Lokomat helps. On one hand, patients can train more accurately and more
intensively, and on the other, therapists can simplify their workflow
and assessment of patient progress. And the fact that these beliefs are
not only being embraced by the institutions in the field, but are also
supported by more than 250 published scientific papers, is an important
step forward for rehabilitation therapy.
“Guidelines for Adult Stroke Rehabilitation and Recovery”
“First-Ever AHA/ASA Stroke Rehab Guidelines Support IRFs,
A successful therapy begins in patients’ heads. In the firm belief that
– step by step – they can reach their goals and regain quality of life.
This is what we work for at the Swiss medtech company Hocoma. With
technologies and ideas that look at functional movement therapy from a
completely different angle. Because they enable independent exercises
and create maximum motivation. Because they challenge people to take
courage and support their hopes with personal achievements.
We are committed to creating the ideal therapy. Our awarded robotic and
sensor-based devices offer solutions for intensive gait therapy
(Lokomat®, Andago®), functional therapy of the upper extremities
(Armeo®), robotic mobilization and functional electrical stimulation in
early rehabilitation (Erigo®) as well as functional movement therapy
within low back pain treatment (Valedo® Therapy Concept) at home and at
the clinic. They are the result of intensive research, consistent
development and continuous exchange with patients, therapists and
partners in research and science.
Those who see to break new grounds need to stay open to exceptional
ideas. They have the potential of being exceptionally effective. This
guiding principle by Hocoma founder and CEO Dr. Gery Colombo has
accompanied us since our start in 2000 and is still lived and
implemented by our dedicated employees around the world. Hocoma is
headquartered in Volketswil near Zurich, Switzerland with subsidiaries
in the USA, Singapore and Slovenia.
All Hocoma products are medical devices
and must be used in strict adherence to the User Manual; failure to do
so may result in serious personal injury. It is strongly recommended
that you regularly consult Hocoma’s website (www.hocoma.com/legalnotes)
for the latest available information. Please contact Hocoma in case of
Use only under the supervision of qualified medical personnel. However,
certain Hocoma products are marketed for home use and must be strictly
used according to the recommendations of your medical care provider who
is knowledgeable about your specific needs. Consult the User Manual and
Hocoma’s website (www.hocoma.com/legalnotes)
for appropriate product designation. Failure to obtain and follow the
recommendations of your medical care provider may result in serious
This information provides details about medical products which may not
be available in all countries and may not have received approval or
market clearance by all governmental regulatory bodies throughout the
world. Nothing herein should be construed as a solicitation or promotion
of any product or of an indication of any specific use for any product
which is not authorized by the laws and regulations of the country where
the reader of this information resides.